Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Sponsor: Pfizer
Terminated
A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
Other terminated trials from Pfizer
Other Epithelial Ovarian Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Epithelial Ovarian Cancer and Fallopian Tube Cancer and is currently terminated or withdrawn. Pfizer leads this study, which shows 17 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Dec 2024 — Present [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE2 → PHASE1/PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Terminated PHASE2
Phase: PHASE1/PHASE2 → PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 12 earlier versions
-
Jan 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .